Downregulation of miR-302c and miR-520c by 1,25(OH)2D3 treatment enhances the susceptibility of tumour cells to natural killer cell-mediated cytotoxicity

British Journal of Cancer

Volumn 109, Issue 3, 2013, Pages 723-730

  Min, D ^a   Lv, X B ^b   Wang, X ^b   Zhang, B ^b   Meng, W ^c   Yu, F ^b   Hu, H ^a  

^a SHANGHAI JIAO TONG UNIVERSITY AFFILIATED SIXTH PEOPLE S HOSPITAL   (China)

^b SUN YAT SEN UNIVERSITY   (China)

^c SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CALCITRIOL; GAMMA INTERFERON; GRANZYME B; MICRORNA; MICRORNA 302C; MICRORNA 520C; NATURAL KILLER CELL RECEPTOR NKG2D; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ARTICLE; CANCER SUSCEPTIBILITY; CELL ACTIVATION; CELL MEDIATED CYTOTOXICITY; CELL VIABILITY; DOWN REGULATION; GENE EXPRESSION; NATURAL KILLER CELL; PRIORITY JOURNAL; TUMOR CELL; UPREGULATION;

CALCITRIOL; CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; DOWN-REGULATION; HEK293 CELLS; HEMATOLOGIC NEOPLASMS; HUMANS; IMMUNITY, CELLULAR; IMMUNOTHERAPY, ADOPTIVE; K562 CELLS; KILLER CELLS, NATURAL; MCF-7 CELLS; MICRORNAS; NEOPLASMS;

EID: 84883179046     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.337     Document Type: Article

References (29)

1. Brandt CS, Baratin M, Yi EC, Kennedy J, Gao Z, Fox B, Haldeman B, Ostrander CD, Kaifu T, Chabannon C,Moretta A, West R, Xu W, Vivier E, Levin SD (2009) The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans. J Exp Med 206: 1495-1503.
2. Cai N, Wang YD, Zheng PS (2013) The microRNA-302-367 cluster suppresses the proliferation of cervical carcinoma cells through the novel target AKT1. RNA 19(1): 85-95.
3. Cerwenka A, Baron JL, Lanier LL (2001) Ectopic expression of retinoic acid early inducible-1 gene (RAE-1) permits natural killer cell-mediated rejection of a MHC class I-bearing tumor in vivo. Proc Natl Acad Sci USA 98: 11521-11526.
4. Champsaur M, Lanier LL (2010) Effect of NKG2D ligand expression on host immune responses. Immunol Rev 235: 267-285.
5. Chavez-Blanco A, De la Cruz-Hernandez E, Dominguez GI, Rodriguez-Cortez O, Alatorre B, Perez-Cardenas E, Chacon-Salinas R, Trejo-Becerril C, Taja-Chayeb L, Trujillo JE, Contreras-Paredes A, Duenas-Gonzalez A (2011) Upregulation of NKG2D ligands and enhanced natural killer cell cytotoxicity by hydralazine and valproate. Int J Oncol 39: 1491-1499.
6. Deeb KK, Trump DL, Johnson CS (2007) Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nat Rev 7: 684-700.
7. Diefenbach A, Jensen ER, Jamieson AM, Raulet DH (2001) Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature 413: 165-171.
8. Eisenring M, vom Berg J, Kristiansen G, Saller E, Becher B (2010) IL-12 initiates tumor rejection via lymphoid tissue-inducer cells bearing the natural cytotoxicity receptor NKp46. Nat Immunol 11: 1030-1038.
9. Fernandez-Messina L, Reyburn HT, Vales-Gomez M (2012) Human NKG2D-ligands: cell biology strategies to ensure immune recognition. Front Immunol 3: 299.
10. Guerra N, Tan YX, Joncker NT, Choy A, Gallardo F, Xiong N, Knoblaugh S, Cado D, Greenberg NM, Raulet DH (2008) NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy. Immunity 28: 571-580.
11. Hilpert J, Grosse-Hovest L, Grunebach F, Buechele C, Nuebling T, Raum T, Steinle A, Salih HR (2012) Comprehensive analysis of NKG2D ligand expression and release in leukemia: implications for NKG2D-mediated NK cell responses. J Immunol 189: 1360-1371.
12. Keklikoglou I, Koerner C, Schmidt C, Zhang JD, Heckmann D, Shavinskaya A, Allgayer H, Guckel B, Fehm T, Schneeweiss A, Sahin O, Wiemann S, Tschulena U (2012) MicroRNA-520/373 family functions as a tumor suppressor in estrogen receptor negative breast cancer by targeting NF-kappaB and TGF-beta signaling pathways. Oncogene 31: 4150-4163.
13. Kizildag S, Ates H, Kizildag S (2012) Treatment of K562 cells with 1,25-dihydroxyvitamin D3 induces distinct alterations in the expression of apoptosis-related genes BCL2, BAX, BCLXL, and p21. Ann Hematol 89: 1-7.
14. Lee JH, Park S, Cheon S, Lee JH, Kim S, Hur DY, Kim TS, Yoon SR, Yang Y, Bang SI, Park H, Lee HT, Cho D (2011) 1,25-Dihydroxyvitamin D(3) enhances NK susceptibility of human melanoma cells via Hsp60-mediated FAS expression. Eur J Immunol 41: 2937-2946.
15. Liang Z, Ahn J, Guo D, Votaw JR, Shim H (2013) MicroRNA-302 replacement therapy sensitizes breast cancer Cells to ionizing radiation. Pharm Res 30(4): 1008-1016.
16. Ljunggren HG (2008) Cancer immunosurveillance: NKG2D breaks cover. Immunity 28: 492-494.
17. Mistry AR, O'Callaghan CA (2007) Regulation of ligands for the activating receptor NKG2D. Immunology 121: 439-447.
18. Mondelli MU (2012) NKG2D and its ligands: key to immunotherapy of liver cancer? J Hepatol 56: 308-310.
19. Nausch N, Cerwenka A (2008) NKG2D ligands in tumor immunity. Oncogene 27: 5944-5958.
20. Obeidy P, Sharland AF (2009) NKG2D and its ligands. Int J Biochem Cell Biol 41: 2364-2367.
21. Pegram HJ, Andrews DM, Smyth MJ, Darcy PK, Kershaw MH (2011) Activating and inhibitory receptors of natural killer cells. Immunol Cell Biol 89: 216-224.
22. Saito H, Osaki T, Ikeguchi M (2012) Decreased NKG2D expression on NK cells correlates with impaired NK cell function in patients with gastric cancer. Gastric Cancer 15: 27-33.
23. Trotta R, Chen L, Ciarlariello D, Josyula S, Mao C, Costinean S, Yu L, Butchar JP, Tridandapani S, Croce CM, Caligiuri MA (2012) miR-155 regulates IFN-gamma production in natural killer cells. Blood 119: 3478-3485.
24. Trump DL, Deeb KK, Johnson CS (2010) Vitamin D: considerations in the continued development as an agent for cancer prevention and therapy. Cancer J (Sudbury, Mass) 16: 1-9.
25. Tsuboi S, Sutoh M, Hatakeyama S, Hiraoka N, Habuchi T, Horikawa Y, Hashimoto Y, Yoneyama T, Mori K, Koie T, Nakamura T, Saitoh H, Yamaya K, Funyu T, Fukuda M, Ohyama C (2011) A novel strategy for evasion of NK cell immunity by tumours expressing core2 O-glycans. EMBO J 30: 3173-3185.
26. Vuolo L, Di Somma C, Faggiano A, Colao A (2012) Vitamin D and cancer. Front Endocrinol 3: 58.
27. Wiemann K, Mittrucker HW, Feger U, Welte SA, Yokoyama WM, Spies T, Rammensee HG, Steinle A (2005) Systemic NKG2D down-regulation impairs NK and CD8 T cell responses in vivo. J Immunol 175: 720-729.
28. Yadav D, Ngolab J, Lim RS, Krishnamurthy S, Bui JD (2009) Cutting edge: down-regulation of MHC class I-related chain A on tumor cells by IFN-gamma-induced microRNA. J Immunol 182: 39-43.
29. Zhang J, Zhang H, Zhang X, Yu Z (2013) Synergistic effect of retinoic acid and vitamin D analog EB1089-induced apoptosis of hepatocellular cancer cells. Cytotechnology 65(3): 457-465.